Astellas Pharma Inc (4503):企業の財務・戦略的SWOT分析

◆英語タイトル:Astellas Pharma Inc (4503) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C8764
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:74
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:日本
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥13,375見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥26,750見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥40,125見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Astellas Pharma Inc (4503) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Astellas Pharma Inc (Astellas) is a research based pharmaceutical company that discovers, develops, manufactures, and commercializes a wide range of pharmaceuticals. The company’s product portfolio comprises both marketed products for the treatment of a wide range of urological diseases, infectious diseases, cancer, diseases and disorders of central nervous system (CNS), and metabolic diseases, immunodeficiency diseases, and transplantation. The company is investigating enfortumab vedotin in Phase 2 and Phase 3 clinical trials for the treatment of urothelial cancer; zolbetuximab in Phase 3 clinical trials for the treatment of gastric cancer and gastroesophageal junction cancer; roxadustat in Phase 3 clinical studies for the treatment of patients with anemia associated with chronic kidney disease (CKD) in patients on dialysis and non-dialysis; fezolinetant in Phase 2a clinical trials for the treatment of menopause-related vasomotor symptoms (MR-VMS) such as hot flashes and night sweats; and gilteritinib for the treatment of for acute myeloid leukemia (AML). It operates in the Americas; Europe; and Asia and Oceania through its network of subsidiaries and affiliates. Astellas is headquartered in Tokyo, Japan.

Astellas Pharma Inc Key Recent Developments

Oct 23,2018 Astellas and BANDAI NAMCO entertainment to jointly develop Smartphone Exercise Support App
Oct 16,2018 Cytokinetics Unveils Expanded Development Pipeline and Provides Key Updates on Late-Stage Clinical Research Programs at R&D Day
Oct 09,2018 Astellas details progress and commitment to patients and the community in the company’s americas 2017 corporate social responsibility report card
Oct 09,2018 Astellas, Mitsubishi Tanabe Pharma, and Daiichi Sankyo announce second public recruitment offering of “Joinus”, a joint research program to discover new drugs using drug-repositioning compound library

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Section 1 – About the Company 6
Astellas Pharma Inc – Key Facts 6
Astellas Pharma Inc – Key Employees 7
Astellas Pharma Inc – Key Employee Biographies 11
Astellas Pharma Inc – Major Products and Services 12
Astellas Pharma Inc – History 15
Astellas Pharma Inc – Company Statement 27
Astellas Pharma Inc – Locations And Subsidiaries 28
Head Office 28
Other Locations & Subsidiaries 28
Joint Venture 33
Section 2 – Company Analysis 35
Company Overview 35
Astellas Pharma Inc – Business Description 36
Product Category: Betanis/Myrbetriq/BETMIGA 36
Performance 36
Product Category: Other 37
Performance 37
Product Category: Prograf 37
Performance 37
Product Category: Vesicare 37
Performance 37
Product Category: XTANDI 37
Performance 37
Geographical Segment: Americas 37
Performance 37
Geographical Segment: Asia and Oceania 37
Performance 37
Geographical Segment: EMEA 37
Performance 37
Geographical Segment: Japan 38
Performance 38
R&D Overview 38
Astellas Pharma Inc – Corporate Strategy 39
Astellas Pharma Inc – SWOT Analysis 40
SWOT Analysis – Overview 40
Astellas Pharma Inc – Strengths 40
Astellas Pharma Inc – Weaknesses 41
Astellas Pharma Inc – Opportunities 42
Astellas Pharma Inc – Threats 43
Astellas Pharma Inc – Key Competitors 44
Section 3 – Company Financial Ratios 45
Financial Ratios – Capital Market Ratios 45
Financial Ratios – Annual Ratios 46
Performance Chart 49
Financial Performance 49
Financial Ratios – Interim Ratios 50
Financial Ratios – Ratio Charts 51
Section 4 – Company’s Lifesciences Financial Deals and Alliances 52
Astellas Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 52
Astellas Pharma Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 53
Astellas Pharma Inc, Recent Deals Summary 54
Section 5 – Company’s Recent Developments 55
Oct 23, 2018: Astellas and BANDAI NAMCO entertainment to jointly develop Smartphone Exercise Support App 55
Oct 23, 2018: Astellas and BANDAI NAMCO entertainment to jointly develop Smartphone Exercise Support App 56
Oct 16, 2018: Cytokinetics Unveils Expanded Development Pipeline and Provides Key Updates on Late-Stage Clinical Research Programs at R&D Day 57
Oct 09, 2018: Astellas details progress and commitment to patients and the community in the company’s americas 2017 corporate social responsibility report card 60
Oct 09, 2018: Astellas, Mitsubishi Tanabe Pharma, and Daiichi Sankyo announce second public recruitment offering of “Joinus”, a joint research program to discover new drugs using drug-repositioning compound library 61
Oct 05, 2018: Cytokinetics and Astellas Provide Updates Regarding Collaborative Skeletal Muscle Program 62
Sep 18, 2018: Astellas Promotes Geoff Towle to Vice President of Oncology Marketing at Astellas US 66
Aug 14, 2018: Astellas Pharma acquires Quethera for $108.5m 67
Jun 08, 2018: Astellas names Nahrin Marino to Vice President, Head of Ethics & Compliance Americas 68
May 31, 2018: Astellas Oncology C3 Prize Returns for Third Year with Focus on Improving Cancer Care in Underserved Regions of the World 69
Section 6 – Appendix 70
Methodology 70
Ratio Definitions 70
About GlobalData 74
Contact Us 74
Disclaimer 74

List of Tables
Astellas Pharma Inc, Key Facts 6
Astellas Pharma Inc, Key Employees 7
Astellas Pharma Inc, Key Employees (cont..) 10
Astellas Pharma Inc, Key Employee Biographies 11
Astellas Pharma Inc, Major Products and Services 12
Astellas Pharma Inc, History 15
Astellas Pharma Inc, Other Locations 28
Astellas Pharma Inc, Subsidiaries 28
Astellas Pharma Inc, Joint Venture 33
Astellas Pharma Inc, Key Competitors 44
Astellas Pharma Inc, Ratios based on current share price 45
Astellas Pharma Inc, Annual Ratios 46
Astellas Pharma Inc, Annual Ratios (Cont...1) 47
Astellas Pharma Inc, Annual Ratios (Cont...2) 48
Astellas Pharma Inc, Interim Ratios 50
Astellas Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 52
Astellas Pharma Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 53
Astellas Pharma Inc, Recent Deals Summary 54
Currency Codes 70
Capital Market Ratios 70
Equity Ratios 71
Profitability Ratios 71
Cost Ratios 72
Liquidity Ratios 72
Leverage Ratios 73
Efficiency Ratios 73

List of Figures
Astellas Pharma Inc, Performance Chart (2014 - 2018) 49
Astellas Pharma Inc, Ratio Charts 51
Astellas Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 52
Astellas Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 53

★海外企業調査レポート[Astellas Pharma Inc (4503):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Grifols, S.A. (GRF):企業のM&A・提携動向(医療機器分野)
    Summary Grifols, S.A. (Grifols) is a pharmaceutical and chemical company focused at improving the health and well being of people around the world. It carries out the research, development, manufacturing and marketing of plasma-derived therapies, diagnostic products and hospital pharmacy products.. …
  • Falck Renewables S.p.A. (FKR):企業の財務・戦略的SWOT分析
    Falck Renewables S.p.A. (FKR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • The Company for Cooperative Insurance (8010):企業概要およびSWOT分析
    This report is a crucial resource for industry executives and anyone looking to access key information about "The Company for Cooperative Insurance" The report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. Timet …
  • BlueScope Steel Ltd:企業のM&A・事業提携・投資動向
    BlueScope Steel Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's BlueScope Steel Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), …
  • Assystem SA (ASY)-エネルギー分野:企業M&A・提携分析
    Summary Assystem S.A. (Assystem) is a provider of engineering and innovation consultancy services. Through coordinating with clients, the company designs and develops across the life cycle products and services. It offers various R&D services range from functional analysis to commissioning by design …
  • Indiana Municipal Power Agency-エネルギー分野:企業M&A・提携分析
    Summary Indiana Municipal Power Agency (IMPA) is a not-for-profit wholesale power provider supplying power to cities and communities across Indiana and Ohio. The agency was formed by its member utilities which enable them to share power resources and provide electricity economically to their custome …
  • Matheson Tri-Gas, Inc.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Matheson Tri-Gas, Inc. Mergers …
  • Antares Energy Limited:企業のM&A・提携動向(石油・ガス分野)
    Summary Antares Energy Limited (Antares Energy) is an oil and gas company that acquires, explores, and develops oil and gas properties. The company’s projects comprise Southern Star, Big Star, Northern Star, and Oyster Creek. Antares Energy’s Southern Star project is located in the core of the main …
  • China CITIC Bank Corporation Limited:企業の戦略・SWOT・財務分析
    SummaryChina CITIC Bank Corporation Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the …
  • Amberley Group plc:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Amberley Group plc Mergers and …
  • Mesa Laboratories Inc (MLAB)-医療機器分野:企業M&A・提携分析
    Summary Mesa Laboratories Inc (Mesa) is a medical device company that manufactures and markets validation and monitoring instruments. The company’s products comprise mesa biological indicators, DryCal gas flow calibrators, BGI ambient particulate sampling, DialyGuard dialysate meters, SureTorque cap …
  • Sysmex Corp (6869):企業の製品パイプライン分析2018
    Summary Sysmex Corp (Sysmex) is a supplier of medical devices. It researches, develops, manufactures and sells instruments, reagents, and software applications that facilitate health checkups, treatment and disease management. The company offers diagnostic instruments, reagents and laboratory inform …
  • Husky Energy Inc (HSE)-石油・ガス分野:企業M&A・提携分析
    Summary Husky Energy Inc. (Husky) is an integrated oil and gas company. The company has operations in upstream and downstream sectors of oil and gas value chain. Its upstream operations include the exploration, development and production of crude oil, bitumen and natural gas. Husky also carried out …
  • Gleiss Lutz Hootz Hirsch GmbH:企業の戦略的SWOT分析
    Summary Gleiss Lutz Hootz Hirsch GmbH (Gleiss Lutz) is a legal advisory firm. It provides a broad spectrum of advisory services in various fields including banking and finance, capital markets, competition or antitrust, compliance, dispute resolution, employment, mergers and acquisitions, patents, l …
  • SBI Holdings, Inc.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' SBI Holdings, Inc. Mergers and …
  • Mitsubishi Heavy Industries, Ltd.:戦略・SWOT・企業財務分析
    Mitsubishi Heavy Industries, Ltd. - Strategy, SWOT and Corporate Finance Report Summary Mitsubishi Heavy Industries, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Qvella Corp:医療機器:M&Aディール及び事業提携情報
    Summary Qvella Corp (Qvella) is a molecular diagnostics company which develops differentiated technology for rapid detection of pathogens causing Sepsis by direct sampling of bodily fluids. Its Field Activated Sample Treatment (FAST) -ID technology utilizes a novel electrical lysing and sample treat …
  • Simpson Manufacturing Co., Inc.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Simpson Manufacturing Co., Inc. …
  • Medical Research Council Technology:企業のM&A・提携動向(医療分野)
    Summary Medical Research Council Technology (MRC Technology) is a life science medical research charity that offers research services. The organization’s activities include identifying and evaluating research, investing in promising projects, protecting assets with potential, and partnering with ind …
  • Kyorin Pharmaceutical Co Ltd:企業のM&A・提携動向(医療分野)
    Summary Kyorin Pharmaceutical Co Ltd (Kyorin), a subsidiary of KYORIN Co.,Ltd. manufactures and markets generic products. The company manufactures and sells prescribed medicines including ethical drugs, mucodyne, kipres, pentasa, ketas and uritos. Its KETAS is a phosphodiesterase inhibitor agent for …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆